Aerojet Rocketdyne selected to power Navy’s CRAW torpedo

Navy’s new Compact Rapid Attack Weapon (CRAW) is the next generation Navy torpedo (Seapower contributed)

HUNTSVILLE — Aerojet Rocketdyne will power the Navy’s new Compact Rapid Attack Weapon as part of the Raytheon Missiles & Defense team building the next generation torpedo.

Aerojet Rocketdyne’s Huntsville facility is the hub for propulsion technology and will provide the afterbody, propulsion system and tail for the new torpedo.

“In all domains – from deep sea to deep space – Aerojet Rocketdyne is committed to being a trusted partner to provide reliable, innovative propulsion technology to protect our service members and enable national defense,” said Eileen P. Drake, Aerojet Rocketdyne CEO and president.

Aerojet Rocketdyne will leverage its more than 60 years of naval expertise to deliver next generation propulsion for the CRAW torpedo. The torpedo will use an innovative Stored Chemical Energy Propulsion System, which will significantly improve its capabilities, the company said.

In February, Aerojet Rocketdyne announced it built a self-funded SCEPS lithium boiler. In addition to its use on CRAW, the Navy is contracting with Aerojet Rocketdyne to develop SCEPS for the Navy’s larger MK 54 MOD 2 torpedo.

The company will produce the afterbody, propulsion system and tail for the new CRAW torpedo at its Coleman Aerospace subsidiary, Aerojet Rocketdyne’s Center of Excellence for undersea propulsion.

According to the Navy, CRAW will be used offensively against enemy submarines and can serve as a defensive weapon to eliminate incoming torpedoes.

Recent in Business

Pharmaceutical Reform Alliance has a new report

FULL REPORT HERE: https://www.pharmareformalliance.com/affordabilityreport/  Today, the Pharmaceutical Reform Alliance (PRA) released a report explaining how the pharmaceutical industry’s anti-competitive and anti-consumer business practices have led to higher healthcare costs, contributing to America’s […]

The Pharmaceutical Reform Alliance (PRA) has released a report explaining how the pharmaceutical industry’s anti-competitive and anti-consumer business practices have led to higher healthcare costs, contributing to America’s affordability crisis. […]

Next Post

Alabama Big 10 Mayors urge voters to support Aniah’s Law

Bud McLaughlin October 24, 2022